-

Sage Therapeutics to Present at Upcoming August Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:

  • 2021 Wedbush PacGrow Healthcare Virtual Conference: Barry Greene, Chief Executive Officer of Sage Therapeutics, will be a featured speaker on the panel, The Brains of the Operation - Novel Approaches in Neuro, on Tuesday, August 10, 2021 at 12:00 p.m. ET.
  • Canaccord Genuity 41st Annual Growth Conference: fireside chat on Wednesday, August 11, 2021 at 8:00 a.m. ET.

A live webcast of each event can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

Contacts

Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com

Sage Therapeutics, Inc.

NASDAQ:SAGE

Release Versions

Contacts

Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com

More News From Sage Therapeutics, Inc.

Sage Therapeutics Announces R&D Leadership Transition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on...

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we believe it will continue to be instrumental in accelerating progress in maternal mental health,” said Barry Greene,...

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeu...
Back to Newsroom